ZENAVOD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZENAVOD (ZENAVOD).
ZENAVOD is a monoclonal antibody that targets the EphA2 receptor, inhibiting its tyrosine kinase activity and downstream signaling pathways involved in tumor angiogenesis and proliferation.
| Metabolism | Metabolized via proteolytic degradation into small peptides and amino acids; not metabolized by cytochrome P450 enzymes. |
| Excretion | Renal: 60% as unchanged drug, Biliary/Fecal: 30% as metabolites, 10% unchanged |
| Half-life | Terminal elimination half-life: 12 hours (range 10-14 hr); supports once-daily dosing in most patients. |
| Protein binding | 94% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Vd: 1.2 L/kg (extensive tissue distribution, high intracellular penetration) |
| Bioavailability | Oral: 75% (fasting); reduced by 20% with high-fat meal. |
| Onset of Action | Oral: 1-2 hours; Intravenous: 5-10 minutes. |
| Duration of Action | 24 hours for bacteriostatic effect; clinical response sustained with daily dosing. |
| Molecular Weight | 512.34 |
10 mg orally once daily
| Dosage form | CAPSULE |
| Renal impairment | No adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (eGFR < 30 mL/min/1.73 m2). |
| Liver impairment | No adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No specific dose adjustment required. Clinical studies included patients >65 years; no overall differences in safety or efficacy observed. |
| 1st trimester | ZENAVOD (generic name: zenavod) is an investigational drug with no published human pregnancy data. Animal studies show embryotoxicity at high doses. Avoid use unless potential benefit justifies potential risk. |
| 2nd trimester | No human data. Animal studies indicate potential for fetal growth restriction. Use only if clearly needed. |
| 3rd trimester | No human data. May cause neonatal adverse effects due to placental transfer. Use only if benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for ZENAVOD (ZENAVOD).
| Placental transfer | Crosses placenta in animal models; human transfer expected based on molecular weight and lipophilicity. |
| Breastfeeding | No data on excretion into human milk. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for 2 weeks after last dose. |
■ FDA Black Box Warning
No FDA-issued black box warning as of the current data.
| Serious Effects |
Hypersensitivity to Zenavod or any excipientSevere hepatic impairment (Child-Pugh C)Concomitant use with strong CYP3A4 inducers
| Precautions | Infusion-related reactions, Cardiotoxicity including left ventricular dysfunction, Thromboembolic events, Ocular toxicity including keratitis and uveitis |
| Food/Dietary | No known direct food interactions. However, patients with Pompe disease may require a high-protein, low-carbohydrate diet to support muscle function and glycogen regulation. Avoid grapefruit and grapefruit juice as they may alter drug metabolism via CYP3A4 inhibition, though clinical significance is unknown. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | No human data; animal studies show developmental toxicity at maternal toxic doses. First trimester: potential for teratogenicity based on animal findings. Second and third trimesters: risk of fetal toxicity (e.g., low birth weight, skeletal variations) at high doses. |
| Fetal Monitoring | Monitor maternal liver function tests, blood counts, and renal function. Fetal monitoring includes growth scans and amniotic fluid index assessment during second and third trimesters. |
| Fertility Effects | Animal studies indicate impaired fertility at high doses; human data lacking. May cause reversible menstrual irregularities. |
| Clinical Pearls |
| ZENAVOD (avalglucosidase alfa) is a recombinant human acid alpha-glucosidase indicated for Pompe disease. Administer pretreatment with antihistamines and corticosteroids to mitigate infusion-associated reactions. Monitor for anaphylaxis and severe allergic reactions during infusion. Assess cardiac function prior to initiation due to risk of arrhythmias and hypertrophic cardiomyopathy. Use with caution in patients with impaired renal function as enzyme replacement therapy may exacerbate proteinuria. |
| Patient Advice | ZENAVOD is an enzyme replacement therapy for Pompe disease that helps break down glycogen in muscle cells. · You will receive this medication as an intravenous infusion every 2 weeks; treatment is lifelong. · Before each infusion, you may receive medications to reduce the risk of allergic reactions. · Common side effects include headache, fever, chills, nausea, and fatigue; report severe reactions like difficulty breathing or swelling of the face. · Inform your healthcare provider of all medications, including over-the-counter drugs and supplements. · Do not drive or operate heavy machinery if you experience dizziness or drowsiness after infusion. |